Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citchem D is an oral combination syrup developed by Ultrachem Pharmaceuticals for the treatment of cough and related respiratory symptoms. The formulation contains four active ingredients: bromhexine (a mucolytic agent), dextromethorphan (a centrally acting antitussive), ammonium chloride (an expectorant), and menthol (a soothing agent). Bromhexine works by thinning and reducing the viscosity of mucus in the respiratory tract, facilitating its clearance. Dextromethorphan acts on the central nervous system, specifically as a sigma-1 receptor agonist and NMDA receptor antagonist, to suppress the cough reflex. Ammonium chloride acts as an expectorant by irritating the gastric mucosa, reflexively increasing respiratory tract secretions to ease sputum expulsion. Menthol provides a cooling and local anesthetic effect, soothing throat irritation. Together, these components provide comprehensive relief from productive and non-productive coughs associated with bronchitis, colds, and other bronchopulmonary disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citchem D.